Apyx Medical initiated with a Neutral at BTIG

BTIG analyst Sam Eiber initiated coverage of Apyx Medical with a Neutral rating and no price target The advanced energy company competes in the cosmetic surgery market with its Renuvion platform, which the firm calls a “unique,” minimally invasive skin tightening platform backed by “robust” clinical data. The firm sees positives, but recognizes that demand for aesthetic capital equipment and procedures has contracted in recent quarters in a challenging macroeconomic environment and adds that Apyx remains unprofitable and faces near-term financing challenges that the firm expects to remain an overhang on shares.